Ruxolitinib in GvHD (RIG) study: A multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

BMC Cancer

Volumn 18, Issue 1, 2018, Pages

  Von Bubnoff, Nikolas ^a,b   Ihorst, Gabriele ^a   Grishina, Olga ^a   Röthling, Nadine ^c   Bertz, Hartmut ^a,b   Duyster, Justus ^a,b   Finke, Jürgen ^a,b   Zeiser, Robert ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Biomarkers; Inflammatory cytokines; JAK inhibitor; Ruxolitinib; Steroid refractory GvHD

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; RUXOLITINIB; STEROID; JANUS KINASE; PYRAZOLE DERIVATIVE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ARTICLE; CONTROLLED STUDY; CYTOKINE BLOOD LEVEL; DISEASE SEVERITY; DRUG EFFICACY; ENTEROPATHY; EVENT FREE SURVIVAL; FAILURE FREE SURVIVAL; FEMALE; GRAFT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SKIN DISEASE; SYSTEMIC THERAPY; TREATMENT FAILURE; TREATMENT RESPONSE; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG EFFECT; DRUG RESISTANCE; GRAFT VERSUS HOST REACTION; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; OUTCOME ASSESSMENT; PROCEDURES; RETROSPECTIVE STUDY;

ADULT; AGED; DRUG RESISTANCE; FEMALE; GRAFT VS HOST DISEASE; HUMANS; JANUS KINASES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; PYRAZOLES; RETROSPECTIVE STUDIES; STEROIDS;

EID: 85056740412     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-018-5045-7     Document Type: Article

References (24)

1. Filipovich AH, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-56.
2. Ferrara JL, et al. Graft-versus-host disease. Lancet. 2009;373(9674):1550-61.
3. Onishi C, et al. A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease. Int J Hematol. 2010;91(3):464-70.
4. Xhaard A, et al. Steroid-refractory acute GVHD: lack of long-term improved survival using new generation Anticytokine treatment. Biol Blood Marrow Transplant. 2011.
5. Arai S, et al. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant. 2002;8(3):155-60.
6. Jaksch M, Mattsson J. The pathophysiology of acute graft-versus-host disease. Scand J Immunol. 2005;61(5):398-409.
7. Ferrara JL. Advances in the clinical management of GVHD. Best Pract Res Clin Haematol. 2008;21(4):677-82.
8. Zeiser R, Blazar BR. Acute graft-versus-host disease - biologic process, prevention, and therapy. N Engl J Med. 2017;377(22):2167-79.
9. Paczesny S, et al. New perspectives on the biology of acute GVHD. Bone Marrow Transplant. 2010;45(1):1-11.
10. Jenq RR, Ubeda C, Taur Y, Menezes CC, Khanin R, Dudakov JA, et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med. 2012;209:903-11.
11. Schwab L, Goroncy L, Palaniyandi S, Gautam S, Triantafyllopoulou A, Mocsai A, Reichardt W, Karlsson FJ, Radhakrishnan SV, Hanke K, Schmitt-Graeff A, Freudenberg M, von Friederike D, Loewenich FD, Wolf P, Leonhardt F, Baxan N, Pfeifer D, Schmah O, Schönle A, Martin SF, Mertelsmann R, Duyster J, Finke J, Prinz M, Henneke P, Häcker H, Hildebrandt GC, Häcker G, Zeiser R. Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance GvHD via tissue damage. Nat Med. 2014. https://doi.org/10.1038/nm.3517.
12. Kalyan S, Kabelitz D. When neutrophils meet T cells: beginnings of a tumultuous relationship with underappreciated potential. Eur J Immunol. 2014;44:627-33.
13. Shimoda K, et al. Jak1 plays an essential role for receptor phosphorylation and stat activation in response to granulocyte colony-stimulating factor. Blood. 1997;90(2):597-604.
14. Nicholson SE, et al. Tyrosine kinase JAK1 is associated with the granulocyte-colony-stimulating factor receptor and both become tyrosine-phosphorylated after receptor activation. Proc Natl Acad Sci U S A. 1994;91(8):2985-8.
15. Verstovsek S, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-27.
16. Verstovsek S, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
17. Spoerl S, Mathew NR, Bscheider M, Schmitt-Graeff A, Chen S, Mueller T, Verbeek M, Fischer J, Otten V, Schmickl M, Maas-Bauer K, Finke J, Peschel C, Duyster J, Poeck H, Zeiser R, von Bubnoff N. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood. 2014;123(24):3832-42.
18. Zeiser, R., et al., Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood, 2006. 108(1): p. 390-9.
19. Zeiser R, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29(10):2062-8.
20. Zeiser, R., et al., Long-term follow-up of patients with corticosteroid-refractory graft-versus-host disease treated with ruxolitinib. Blood (ASH Annual Meeting Abstracts), 2016. 128(22): p. abstract 4561.
21. Schroeder, M.A., et al. A Phase I Trial of Janus Kinase (JAK) Inhibition with INCB039110 in Acute Graft-Versus-Host Disease (aGVHD). In 2016 ASH Annual Meeting. 2016. San Diego, CA.
22. Onkopedia/DGHO, Leitlinie: Graft-versus-Host Erkrankung, akut. 2017.
23. Harris AC, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai acute GVHD international consortium. Biol Blood Marrow Transplant. 2016;22(1):4-10.
24. Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 Scoring Manual (3rd edition). Brussels: European Organisation for Research and Treatment of Cancer; 2001.